Kundi Quoted on FDA Committee Approval of Peptide Compounds

NPR

Longevity & Healthspan Industry Co-Leader Abha Kundi, a former US Food and Drug Association (FDA) regulatory counsel, was quoted on a recent vote from an FDA advisory committee that recommended six (out of seven) peptide substances for lawful compounding.

While the FDA leadership doesn’t have to follow the recommendation of the committee, Abha noted that ignoring them and not changing the legality of these peptides would likely result in lawsuits from the industry.

However, she added that the FDA is “very attuned” to the real-world landscape and the current availability of these products.

“In many ways, the toothpaste is out of the tube here. I think that is absolutely part of the calculus,” she said.

Read the full article here.